Results 101 to 110 of about 2,105 (188)

Marimastat altered the hepatic fibrosis-related gene expression profile by downregulation of multiple pro-fibrogenic transcripts following repeated carbon tetrachloride (CCl4) administration.

, 2013
Hepatic procollagen α1(I) (A), β6 integrin (B), TGF-β1 (C), TGF-β2 (D), α-SMA (E) and TIMP-1 (F) expression as quantified by real-time RT-PCR in total liver RNA.
Hau D. Le (343378), Vincent E. de Meijer (343377), Deanna Y. Sverdlov (363722), Yury Popov (343381), Detlef Schuppan (204756), Vânia Nosé (5653522), Mark Puder (343382), Jonathan A. Meisel (343379)   +7 more
core   +1 more source

Targeting the core program of metastasis with a novel drug combination

Cancer Medicine
Background We previously reported that metastases are generally characterized by a core program of gene expression that activates tissue remodeling/vascularization, alters ion homeostasis, induces the oxidative metabolism, and silences extracellular ...
Gulimirerouzi Fnu, Georg F. Weber
doaj   +1 more source

In vitro inhibition of snake venom toxins by varespladib, marimastat, nafamostat and dimercaprol

Toxicon
Snakebite envenoming causes more than 130,000 deaths and more than 400,000 disabilities per year and has been classified as a priority Neglected Tropical Disease by the World Health Organization (WHO). While antivenom therapy remains the mainstay of snakebite treatment, small molecule therapeutics (SMTs) have been proposed as potential adjuncts to ...
Anandie le Roux, Stephanus J. Cloete, Jacobus P. Petzer, Anél Petzer   +3 more
openaire   +2 more sources

Snakebite drug discovery: high-throughput screening to identify novel snake venom metalloproteinase toxin inhibitors

Frontiers in Pharmacology
Snakebite envenoming results in ∼100,000 deaths per year, with close to four times as many victims left with life-long sequelae. Current antivenom therapies have several limitations including high cost, variable cross-snake species efficacy and a ...
Rachel H. Clare, Rachel H. Clare, Charlotte A. Dawson, Charlotte A. Dawson, Adam Westhorpe, Adam Westhorpe, Laura-Oana Albulescu, Laura-Oana Albulescu, Christopher M. Woodley, Nada Mosallam, Daniel J. W. Chong, Jeroen Kool, Neil G. Berry, Paul M. O’Neill, Nicholas R. Casewell, Nicholas R. Casewell   +15 more
doaj   +1 more source

Heparin-binding EGF-like growth factor via miR-126 controls tumor formation/growth and the proteolytic niche in murine models of colorectal and colitis-associated cancers

Cell Death and Disease
MicroRNAs, including the tumor-suppressor miR-126 and the oncogene miR-221, regulate tumor formation and growth in colitis-associated cancer (CAC) and colorectal cancer (CRC).
Yousef Salama, Shinya Munakata, Taro Osada, Satoshi Takahashi, Koichi Hattori, Beate Heissig   +5 more
doaj   +1 more source

A critical role for matrix metal loproteinases in liver regeneration

, 2008
Background. Matrix metalloproteinases (MMPs), tumor necrosis factor-alpha (TNF-alpha), and interleukin-6 (IL-6) are mediators of liver regeneration. To determine whether MMPs are required for normal hepatic regeneration, we performed 67% hepatectomies on
Kim, Sendia, Puder, Mark, Alwayn, Ian P. J., Verbesey, Jennifer E., Greene, Arin K., Novak, Katherine, Roy, Roopali, Lee, Sang, Moses, Marsha A., Arsenault, Danielle A., Laforme, Andrea   +10 more
core   +1 more source

Phase II Trial of Temozolomide Plus the Matrix Metalloproteinase Inhibitor, Marimastat, in Recurrent and Progressive Glioblastoma Multiforme

, 2002
PURPOSE: Novel therapies are needed for patients with recurrent glioblastoma multiforme (GBM). Because there is evidence that temozolomide (TMZ) has some activity in GBM and is well tolerated, and because of laboratory evidence that metalloproteinases ...
Victor A. Levin, Kenneth R. Hess, Morris D. Groves, Pamela Peterson, Kurt A. Jaeckle, Vinay K. Puduvalli, W.K. Alfred Yung   +6 more
core   +1 more source

Marimastat reversed hepatic steatosis in diet-induced obese mice as well as in ob/ob animals, as demonstrated by histology and magnetic resonance spectroscopy.

, 2013
Representative liver sections stained with hematoxylin and eosin (H&E; top panels; original magnification 200×), and Oil Red O (ORO; middle panels; original magnification 200×).
Hau D. Le (343378), Vincent E. de Meijer (343377), Yury Popov (343381), Anisha K. Sharma (343380), Mark Puder (343382), Jonathan A. Meisel (343379)   +5 more
core   +1 more source

Supplemental Figure S3 and Supplemental Figure S4 from ADAM17 is a Tumor Promoter and Therapeutic Target in Western Diet–associated Colon Cancer

, 2017
Supplemental Figure S3. Marimastat suppresses colonic EGFR signals. Mice received vehicle or marimastat and were fed WD. After 2 wks, colonic proteins measured by WB. A. Alzet pump. B. Protocol. C. EGFR signals. D.
Marc Bissonnette (232543), Farhana Sadiq (14995644), Devkumar Mustafi (774851), Loren Joseph (9921015), Urszula Dougherty (9920988), Joel Pekow (3140316), Vani Konda (13796914), Fatma Ayaloglu-Butun (9920997), Abdurahman Khalil (15010073), Alessandro Fichera (819781), Yan Chun Li (9921018), Reba Mustafi (9920991), Sarbani Adhikari (15010070), Katherine Meckel (15006288), John Hart (379033), Michelle Fletcher (3024933), Haider I. Haider (15006291)   +16 more
core   +1 more source

MMP inhibitors facilitate INH killing of Mtb.

, 2018
(A): Experimental setting of Marimastat’s effect in lung infection model (n = 5). (B): CFU count of 2 groups (PBS and Marimastat) at Day 14, and 4 groups (PBS, Marimastat, INH and Mariamstat+INH) at Day 28 post infection.
Veronique Dartois (2283115), Lu Huang (211625), Yitian Xu (5146028), Xiling Shen (184092), Evgeniya V. Nazarova (5146040), Pengcheng Bu (5146031), David G. Russell (156949), Matthew D. Zimmerman (1604746), Nikolai Rakhilin (5146037), Kai-Yuan Chen (5146034), Dah-Jiun Fu (5146025), Lihua Wang (14548), Firat Kaya (2919981)   +12 more
core   +1 more source